| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KALA | Common Stock | Sale | -$17K | -9.45K | -4.02% | $1.80* | 226K | Oct 26, 2021 | Direct | F1, F2, F3 |
| transaction | KALA | Common Stock | Sale | -$38.3K | -21.1K | -9.33% | $1.82* | 205K | Oct 27, 2021 | Direct | F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| F3 | Includes 61,166 unvested RSUs. |
| F4 | This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F5 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.84, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |